New medicines offer immense benefits to patients, including fewer side effects, reduced hospitalizations, improved quality of life, increased productivity, and extended life expectancy. However, the process of developing a new drug is long, complex, and requires rigorous safety evaluations to ensure efficacy without undue risks.
On average, a new drug takes at least ten years from initial discovery to market approval, with clinical trials alone taking six to seven years. This journey is not just about innovation—it’s about ensuring patient safety at every stage. This is where pharmacovigilance plays a pivotal role.
Drug Discovery: Finding the Right Target
The drug discovery phase begins with identifying a suitable biological target, such as a protein receptor or biomolecule linked to disease progression.
Key Steps in Drug Discovery
- Target Identification: Finding a biomolecule explicitly associated with a disease.
- Target Validation: Confirming its role in disease progression.
- Lead Compound Screening: Identifying small molecules that interact with the target and display therapeutic activity.
- Optimization: Refining lead compounds for maximum efficacy and safety.
How does pharmacovigilance support drug discovery?
Pharmacovigilance monitors early safety concerns, ensuring that lead compounds do not display toxicity or unexpected side effects before moving to preclinical testing.
Drug Development: Testing for Safety and Efficacy
Once a promising drug candidate is identified, it undergoes preclinical and clinical testing to assess:
- Pharmacodynamics (mechanism of drug action)
- Pharmacokinetics (Absorption, Distribution, Metabolism, Excretion, and Toxicity—ADME/Tox properties)
- Bioavailability (how efficiently it reaches its intended target)
The Role of Pharmacovigilance in Drug Development
Pharmacovigilance is integral at multiple stages:
- Preclinical Phase: Tracks toxicity and potential risks before human trials.
- Clinical Trials (Phases I–III): Monitors adverse effects in controlled studies.
- Post-Marketing Surveillance (Phase IV): Detects long-term or rare side effects in real-world use.
Clinical Trials
Clinical trials involve healthy individuals and patients, testing how well different treatments work under controlled conditions. Beyond proving effectiveness, clinical trials fuel pharmacovigilance, ensuring long-term drug safety beyond approval.
Why Are Clinical Trials Important?
- Prevent disease and minimize illness rates.
- Develop life-saving treatments that enhance survival.
- Improve quality of life by reducing symptoms and side effects.
- Advance diagnostics for better detection of health conditions.
Without proper clinical trials, healthcare professionals would lack evidence-based data, potentially leading to harmful or ineffective therapies.
Phases of Clinical Trials
Clinical trials are conducted in stages, each designed to assess safety, effectiveness, and long-term risks.
Phase 1
- Participants: 20–100 healthy volunteers or patients
- Duration: Several months
- Purpose: Safety, dosage, absorption, metabolism, and organ effects
- Success Rate: ~70% progress to Phase 2
- Note: In this phase it is important to enroll a relatively healthy patient population with as few complications and concomitant diseases as possible. Food effect studies are often conducted to investigate the potential impact of food intake on the absorption of the drug. These studies are usually run as a crossover study, with volunteers being given two identical doses of the drug, one after fasting and one after a meal.
Phase 2
- Participants: Up to several hundred patients
- Duration: Several months to 2 years
- Purpose: Efficacy, short-term side effects, and dose range
- Success Rate: ~33% progress to Phase 3
Phase 3
- Participants: 300–3,000 patients
- Duration: 1 to 4 years
- Purpose: Efficacy, monitoring adverse reactions, and comparing with standard treatments
- Success Rate: ~25–30% progress to Phase 4
- Phase 3 trials aim to: compare the effects of newer drugs with the standard treatment, if there is one find out how well the drug works and how long the effects last find out more about how common and serious any side effects or risks are and about any possible longer term problems that could develop.
Different types of clinical trials and their role in advancing drug development:
1. Controlled Trials
Controlled trials aim to compare a new treatment with an existing standard or placebo to determine effectiveness. Participants are divided into two groups:
- Trial Group: Receives the new treatment
- Control Group: Receives standard treatment or placebo
Why it matters: By comparing results between groups, researchers can confirm whether a treatment’s benefits are due to the medication itself rather than external factors or chance.
Placebo-Controlled Trials: A placebo is designed to mimic the real drug without active ingredients, ensuring participants are not influenced by expectations. For example: If the new drug shows significantly better outcomes, it is deemed effective.
2. Blind Trials
Blind trials prevent participants—and sometimes even researchers—from knowing which treatment is being administered, ensuring unbiased responses.
- Single-Blinded Study: Only the physician knows the treatment assignment; the participant does not.
- Double-Blinded Study: Neither the participant nor the physician knows the treatment.
- Partial-Blinded Study: Some study drugs are blinded, others are open-label (e.g., ZDV + 3TC [open] plus nelfinavir or nelfinavir-placebo [blinded]).
- Open-Label Study: Both the participant and physician know the treatment assignment.
Why Are Blind Trials Important?
- Creates balanced groups with different ages, genders, and health conditions.
- Prevents doctors from making biased selections based on individual patient characteristics.
- Ensures any differences in outcomes are due to the drug, not external factors.
- While clinical trials ensure initial safety and efficacy, the real-world impact of a drug requires ongoing vigilance through pharmacovigilance and regulatory oversight.
Blind trials prevent psychological influences—if a patient knows they’re receiving a drug, they may subconsciously feel better regardless of the treatment’s actual effects.
3. Randomized Trials
Randomization assigns participants to treatment groups using a computerized process, eliminating selection bias.
Benefits:
Regulatory Review and Drug Approval
Once a drug successfully completes preclinical studies and Phases 1–3 clinical trials, pharmaceutical companies submit their findings to regulatory authorities for final approval.
Key Steps:
- Submission of NDA/MAA: Companies provide data on quality, safety, preclinical and clinical results.
- Regulatory Assessment: Agencies review evidence for efficacy and risk-benefit ratio.
- Approval Decision: If found safe and effective, the drug is licensed for commercial use.
- Market Launch: The manufacturer submits marketing authorizations for global distribution.
Post-Marketing Surveillance (Phase 4 Trials)
Even after approval, a drug’s real-world performance may differ from controlled clinical trials. Phase 4 trials allow manufacturers and regulators to:
Purpose:
- Evaluate safety and effectiveness in larger populations
- Monitor long-term and rare side effects
- Improve labeling and guidelines
- Detect interactions when used with other medications
Phase 4 Trial Details:
- Participants: Thousands of patients
- Purpose: Assess benefit/risk, long-term effects, and labeling
- Phase 4 trials aim to find out: •
- how well the drug works when it is used more widely
- the long-term risks and benefits
- more about the possible rare side effects
- Not all Phase IV studies are post-marketing surveillance studies. There are multiple observational designs and evaluation schemes that can be used in Phase IV studies to assess the effectiveness, cost-effectiveness, and safety of an intervention in real-world settings.
Real-world trials, also known as Real-World Evidence (RWE) studies, are designed to evaluate how medical treatments perform in everyday clinical settings, outside the controlled environment of traditional clinical trials.
Real-world trials refer to studies that collect and analyze data from actual patient experiences in routine clinical settings, rather than under the strict protocols of RCTs. These studies provide insights into how a drug performs across diverse populations, healthcare systems, and real-life conditions.
RWE studies analyze data from:
- Electronic Health Records (EHRs): Patient histories, diagnoses, treatments, and outcomes.
- Insurance Claims & Billing Data: Information on prescriptions, procedures, and healthcare utilization.
- Patient Registries: Disease-specific databases tracking long-term outcomes.
- Mobile Health Apps & Wearables: Continuous monitoring of health metrics like heart rate, glucose levels, and activity.
- Social Media & Patient Forums: Self-reported experiences and adverse events.
RWE complements pharmacovigilance by identifying:
- Unexpected adverse drug reactions (ADRs)
- Long-term effectiveness
- New risk factors and interactions
- Cost-effectiveness for broader access
Types of Real-World Studies
- Observational Studies: Monitor outcomes without intervention (e.g., cohort or case-control studies).
- Pragmatic Clinical Trials: Blend RCT rigor with real-world settings.
- Retrospective Analyses: Use existing data to evaluate outcomes.
- Prospective Registries: Follow patients forward in time from a defined point.
References:
- DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
- U.S. Food and Drug Administration (FDA). Step 1: Discovery and Development. https://www.fda.gov/patients/drug-development-process/step-1-discovery-and-development
- World Health Organization (WHO). (2002). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. https://apps.who.int/iris/handle/10665/42493
- EMA. (2022). Good pharmacovigilance practices (GVP). https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices
- U.S. National Library of Medicine (ClinicalTrials.gov). Phases of Clinical Trials. https://clinicaltrials.gov/study/NCT02721019
- FDA. (2023). Drug Trials Snapshots and Development Process. https://www.fda.gov/drugs/information-consumers-and-patients-drugs/drug-trials-snapshots
- Schulz, K. F., & Grimes, D. A. (2002). Blinding in randomised trials: Hiding who got what. The Lancet, 359(9307), 696–700. https://doi.org/10.1016/S0140-6736(02)07816-9
- Giezen, T. J., Mantel-Teeuwisse, A. K., & Leufkens, H. G. M. (2009). Pharmacovigilance of biopharmaceuticals: Challenges remain. Drug Safety, 32(10), 811–817. https://doi.org/10.2165/11316460-000000000-00000
- FDA. (2018). Framework for FDA’s Real-World Evidence Program. https://www.fda.gov/media/120060/download
- Makady, A., et al. (2017). Real-world evidence for regulatory decision making: Challenges and opportunities. Clinical Pharmacology & Therapeutics, 101(2), 211–223. https://doi.org/10.1002/cpt.652
- Sherman, R. E., et al. (2016). Real-world evidence — What is it and what can it tell us? New England Journal of Medicine, 375(23), 2293–2297. https://doi.org/10.1056/NEJMsb1609216